S. 204Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017

2 recorded actions150 of these members are on the 2026 ballotWhat the measure does Read on Congress.gov

Sponsor: Ron Johnson [R-WI]
Cosponsors: 46 · 43 Republicans · 2 Democrats · 1 Independent
Policy area: Health
Committees: Health, Education, Labor, and Pensions Committee, Energy and Commerce Committee
Latest action: May 30, 2018 · Became Public Law No: 115-176.

IntroducedJan 24, 2017
Passed the SenateAug 3, 2017
Passed the HouseMay 22, 2018
Sent to the PresidentMay 24, 2018
Became lawMay 30, 2018

What the measure doesCRS summary

Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017

(Sec. 2) This bill amends the Federal Food, Drug, and Cosmetic Act to exempt, from specified requirements and restrictions under that Act and other laws, the provision of certain unapproved, investigational drugs to a terminally ill patient who has exhausted approved treatment options and is unable to participate in a clinical trial involving the drugs. The manufacturer or sponsor of an eligible investigational drug must report annually to the Food and Drug Administration (FDA) on any use of the drug in accordance with these provisions. The FDA shall post an annual summary report of such use on its website.

The bill limits the liability of a sponsor, manufacturer, prescriber, or dispenser that provides, or declines to provide, an eligible investigational drug to an eligible patient in accordance with the bill.

Written by the nonpartisan Congressional Research Service, describing S. 204 as public Law on May 30, 2018. It is not the text of the measure; a later amendment may have changed what it does.

Roll calls on S. 2042 roll calls on this measure

Choose a roll call

May 22, 2018Each bar: ✓ Yea from the bottom, ✕ Nay aboveMay 22, 2018

How every member votedHouse roll call 214

House May 22, 2018 · the primary vote

On Passage

Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act

Passed

250 Yea 169 Nay 8 not voting

Party-line vote 22 of 419 voting members broke with their own party: 22 Democrats.

Open the official roll call

How the chamber split

One dot per member. Select a seat or a bar to filter the list.

DemocratsRepublicansFilled: YeaRing: NayGrey: not voting or present

By party select a segment to filter

All members427 members

Democratic193 members

Republican234 members

marks half of the votes cast. A party’s majority is the side most of its voting members took.

Cosponsors46 · 43 Republicans · 2 Democrats · 1 Independent

Signing on is not a vote: a member can cosponsor S. 204 and vote against it. 43 signed when it was filed.

Loading the public record

Who lobbied on S. 20449 organizations

Organizations that named S. 204 in a lobbying disclosure. Only those that cited the bill by number appear, so this is a floor, not a full list.

SHIRE PHARMACEUTICALS LLCfiled by SHIRE PHARMACEUTICALS LLC, THE NICKLES GROUP, LLC

Trade (domestic/foreign) · Taxation/Internal Revenue Code · Foreign Relations · Copyright/Patent/Trademark +4 more14 filings · 2nd Quarter (Apr 1 - June 30) 2018Filing

UCB, INC.filed by UCB, INC., THE NICKLES GROUP, LLCIts PAC: UCB, Inc. PAC

Medicare/Medicaid · Health Issues · Budget/Appropriations · Taxation/Internal Revenue Code10 filings · 4th Quarter (Oct 1 - Dec 31) 2018Filing

NOVARTISIts PAC: Novartis Corp. PAC

Trade (domestic/foreign) · Taxation/Internal Revenue Code · Copyright/Patent/Trademark · Health Issues +4 more9 filings · 4th Quarter (Oct 1 - Dec 31) 2018Filing

AMERICAN SOCIETY OF CLINICAL ONCOLOGY

Media (information/publishing) · Budget/Appropriations · Medicare/Medicaid · Tobacco +1 more8 filings · 4th Quarter (Oct 1 - Dec 31) 2018Filing

BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)

Education · Medicare/Medicaid · Health Issues · Budget/Appropriations +1 more8 filings · 3rd Quarter (July 1 - Sep 30) 2018Filing

SAREPTA THERAPEUTICSfiled by TARPLIN, DOWNS & YOUNG, LLCIts PAC: Sarepta Therapeutics, Inc. PAC

Medicare/Medicaid · Health Issues · Budget/Appropriations · Copyright/Patent/Trademark8 filings · 4th Quarter (Oct 1 - Dec 31) 2018Filing

VERTEX PHARMACEUTICALS INCORPORATEDfiled by TARPLIN, DOWNS & YOUNG, LLCIts PAC: Vertex Pharmaceuticals Inc. PAC

Taxation/Internal Revenue Code · Copyright/Patent/Trademark · Medicare/Medicaid · Health Issues +1 more8 filings · 4th Quarter (Oct 1 - Dec 31) 2018Filing

BRISTOL-MYERS SQUIBB COMPANYfiled by THE NICKLES GROUP, LLC, BRISTOL-MYERS SQUIBB COMPANYIts PAC: Bristol-Myers Squibb Co. PAC

Medicare/Medicaid · Budget/Appropriations · Taxation/Internal Revenue Code · Health Issues +3 more7 filings · 2nd Quarter (Apr 1 - June 30) 2018Filing

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAfiled by PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA, BAKER & HOSTETLER LLPIts PAC: Pharmaceutical Research & Manufacturers of America Better Government Committee

Health Issues · Copyright/Patent/Trademark · Medicare/Medicaid · Budget/Appropriations +1 more7 filings · 2nd Quarter (Apr 1 - June 30) 2018Filing

ALLIANCE FOR REGENERATIVE MEDICINEfiled by HOLLAND & KNIGHT LLPIts PAC: Alliance for Regenerative Medicine PAC ARM PAC

Health Issues6 filings · 2nd Quarter (Apr 1 - June 30) 2018Filing

202 disclosures name this measure. Retrieved from LDA.gov on 2026-10-05. Senate Office of Public Records cannot vouch for the data or analyses derived from these data after the data have been retrieved from LDA.gov.